The report covers forecast and analysis for the oral antidiabetic drugs market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD billion). The study includes drivers and restraints of the oral antidiabetic drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral antidiabetic drugs market on a global level.

In order to give the users a comprehensive view of the Oral antidiabetic drugs market, we have included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porters five forces model for the oral antidiabetic drugs market has also been included. The study encompasses a market attractiveness analysis, wherein the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view on the oral antidiabetic drugs market by segmenting the market based on drugs class and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. The drugs class segmentation includes sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. The meglitinides class is further segmented into repaglinide and nateglinide. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into U.S., Canada, China, Japan, and Brazil.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global oral antidiabetic drugs market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.

This report segments the global oral antidiabetic drugs Market as follows:

Global Oral Antidiabetic Drugs Market: Drugs Class Analysis

• Sulfonylureas
  
  
  
  • Glimepiride
  
  
  •  Gliclazide
  
  
  •  Glyburide
  
  
  •  Others
  
  
  
  


• Meglitinides

• Repaglinide


• Nateglinide

• Biguanides
  
  
  
  • Metformin
  
  
  •  Others
  
  
  
  


• Alpha-glucosidase inhibitors
  
  
  
  • Acarbose
  
  
  •  Voglibose
  
  
  •  Others
  
  
  
  


• Others

Global Oral Antidiabetic Drugs Market: Regional Segment Analysis

• North America
  
  
  
  • U.S.
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Asia Pacific
  
  
  • China
  
  
  • Japan
  
  
  • Rest of Asia Pacific
  
  
  
  


• Latin America
  
  
  
  • Brazil
  
  
  
  


• Middle East and Africa